![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity
Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity
![Novavax logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Novavax-logo.gif?t=1590614250&width=430)
May 28, 2020
Novavax is expanding its manufacturing capacity for its COVID-19 vaccine candidate by acquiring a manufacturer in the Czech Republic.
The $167 million acquisition of Praha Vaccines is expected to provide an annual capacity of more than 1 billion doses of antigen for Novavax’s vaccine candidate starting in 2021.
Praha Vaccines is part of the India-based Poonawalla Group that includes the Serum Institute of India, a manufacturer of pediatric vaccines.
Upcoming Events
-
21Oct